Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)
Beigene’s Zanubrutinib (BGB-3111) Receives the US FDA’s Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)
Shots:
- The BT designation follows the P-II trial assessing Zanubrutinib in patients with 1L mantle cell lymphoma
- Beigene’s Zanubrutinib is being evaluated globally in seven P-III trials in multiple areas including one for patients with waldenstrom macroglobulinemia (WM) with zanubrutinib vs ibrutinib and P-II for r/r follicular lymphoma in combination with Gazyva (obinutuzumab)
- Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase (BTK) inhibitor and has also received NMPA’s (CMPA) priority review for r/r MCL and r/ r CLL/SLL in China
Click here to read full press release/ article | Ref: Globe News Wire | Image: Twitter
